Semi-Solid Phase Assay for the Alternative Complement Pathway Activity Assessment (AP<sub>100</sub>) by Kerboua, Kheir Eddine & Djenouhat, Kamal
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Semi-Solid Phase Assay for the 
Alternative Complement Pathway 
Activity Assessment (AP100)
Kheir Eddine Kerboua and Kamal Djenouhat
Abstract
Since the introduction of the most expensive drug in the world (Eculizumab) 
in the therapeutic arsenal of many diseases involving the alternative complement 
pathway (ACP) in their pathophysiology, the unmet need to perform simple 
ACP assays affordable for all countries has become one of the major challenges 
of the contemporary medicine. The assay currently used is AH50, despite it still 
challenging for several laboratories. This educational chapter consists on a detail 
protocol of standardized hemolytic assay AP100 and aims to help clinical labo-
ratories over the world and especially those of the developing and low incomes 
countries to perform it. The procedure is essentially the same as for the timed 
lysis assay and dilution methods (AP50) except the concentration of ACP buf-
fer and the chicken erythrocyte density used to make the gels. In clinical field, 
AP100 has at least nine applications in disease diagnosis and follow-up. AP100 has 
many advantages over the AH50 as it is more reliable for the Eculizumab monitor-
ing and more practical with a purpose to be stored and transported for several 
weeks. AP100 is a portable and easy to use device both at the bedside and in the 
companion medical care.
Keywords: alternative complement pathway, AP100, medicine, simple assay,  
low income countries
1. Introduction
Complement system is the pillar of the immune system by its dual role in 
homeostasis and disease. It is the first line of the innate immunity and augments 
adaptive immunity. Indeed, complement acts as a rapid and efficient immune 
surveillance system that has distinct effects on healthy and altered host cells and 
foreign intruders through a complex cascade of proteases [1]. Activation of the 
pathway occurs through three primary pathways: classical, lectin, and alternative 
pathways. Instead to the other pathways and in addition to properdin as the initiat-
ing molecule, the alternative complement pathway (ACP) is activated via a low 
level of constitutive spontaneous hydrolysis of C3 in a process known as tick-over. 
Importantly, thanks to its amplification loop, ACP plays a major role for the final 
effect of initial specific activation of the classical and lectin complement pathways 
and contributed to 80–90% of any C5 activation regardless the initiating pathway 
[2]. Interestingly, ACP has been shown to play a particularly important role in 
preclinical disease models [3].
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The ACP functional assessment constitutes an unmet need in medicine and 
applied research fields as the health valorization of bio-molecules extracted from 
nature. In clinical field it has at least nine applications in disease diagnosis and 
follow-up. For instance in therapy monitoring, it allows to screen patients respond-
ers to the complement blockers like Eculizumab, a patient with abolished activity 
means that he has no C5 mutation and is considered as eligible to this therapy. 
Furthermore, ACP activity makes possible to assess drug effectiveness at the 
plasmatic level [4]. Moreover, by evaluating ACP function we can predict and avoid 
immune-complex diseases flares and end organs damages as in systemic lupus 
erythematosus (SLE).
For the disease diagnosis, several international consensuses include functional 
hypocomplementemia and ACP abnormalities as a diagnostic criterion:
1. Kidney diseases resulting from abnormal control of ACP especially atypical 
hemolytic uremic syndrome (aHUS), C3 glomerulonephritis (C3GN), and dense-
deposit disease (DDD), as well as atypical postinfectious glomerulonephritis [5].
2. Hypocomplementemia by a hemolytic assay constitutes one point in the 
diagnosis score of EULAR/ACR Lupus Classification Criteria 2017 and useful 
marker for evaluating SLE renal disease activity and outcomes [6].
3. The clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is the 
chronic intravascular hemolysis that is a consequence of unregulated activa-
tion of ACP [7].
4. Individuals deficient in components of the alternative and terminal comple-
ment pathways are highly predisposed to invasive, often recurrent menin-
gococcal infections [8]. The most frequent bacterial meningitides related to 
complement proteins deficiencies are dues to factor B, factor D and membrane 
complex attack proteins deficiency.
Disease presentation ACP proteins involved
Immune complex (IC) diseases, SLE with and 
without glomerulonephritis (GN).
Most of ACP proteins trigger tissue injury because 
ACP constitutes the amplification loop of the 
classical pathway
Severe and often repeated pyogenic infections. Deficiency of C3 either primary, or secondary to 
fH or fI deficiency, or the presence of C3 nephritic 
factors. Can also occur with classical component 
deficiency.
Mesangiocapillary glomerulonephritis (MCGN) 
or membranoproliferative glomerulonephritis 
(MPGN)
C3 deficiency classically caused by C3 nephritic 
factors, also fH deficiency
Neisserial infections, usually recurrent 
meningococcal infections.
Occasionally disseminated N. gonorrhea infections.
Terminal component (C5–8) deficiencies; the 
association is less strong in patients with C9 
deficiency. Patients are usually otherwise healthy.
Severe, occasionally repeated, N. meningitidis 
infections in males
Properdin deficiency or Factor D deficiency (very 
rare, not sex linked)
Paroxysmal nocturnal hemoglobinuria Rare acquired clonal disorder of hemopoietic cells 
which lack glycosylphosphatidylinositol (GPI) 
membrane anchored Complement control proteins 
[(DAF) And CD59].
Table 1. 
Clinical presentations of ACP proteins acquired or genetic abnormalities.
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5. Hypocomplementemic hypersensitivity reactions to synthetic hemodialysis 
membrane at the origin of cardiovascular complication, the most frequent and 
life-threatening complication in hemodialysis [9].
6. Several clinical presentations linked to ACP abnormalities as resumed in 
Table 1 [2].
7. ACP is particularly considered in sepsis, due to its uncontrolled amplification 
in sepsis conditions [10].
2. Protocol
The procedure is essentially the same as for the ACP by kinetic fluid phase assay 
except the concentration of AP buffer and the chicken erythrocyte density used to 
make the gels [11]. A value of 100% of plasma ACP function should be defined by 
the pooled normal human plasmas (NHP standard), prepared from a total of 100 
healthy individuals separate for each sex.
2.1 Samples
Patient serum samples for the functional hemolytic assays need to be fresh, 
that is serum should be separated on the day of venepuncture and used the same 
day, or stored at −80°C. This is probably the single most difficult, yet important, 
step because if the cold chain is broken, the results become impossible to interpret 
correctly [12]. Whole blood, with ethylenediaminetetraacetic acid (EDTA) as the 
anticoagulant can also be used.
Chicken red blood cells (CRBC) was collected in tubes containing Alsever or 
20% (v/v) acid citrate dextrose (ACD) and stored at 4°C.
2.2 Buffers and other reagents
1. Phosphate-buffered saline (PBS) contains: 137 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 8.1 mM Na2HPO. Sodium azide can be added if required.
2. Alternative complement pathway buffer (ACP buffer) is PBS containing 
100 mM ethylene glycol-bis(β-aminoethyl ether)N,N′,N′-tetraacetic acid 
(EGTA) and 7 mM MgCl2; resulting in chelation of Ca
2+, but not Mg2+, and 
providing additional Mg2+ [13]. This prevents complement activation via the 
classical pathway and facilitates complement activation via the ACP in aga-
rose gels. ACP buffer/gelatin contains 1 g/L gelatin and is used when protein 
concentrations are low.
3. Agarose: use an agarose that has a low melting point as plates are easier to pour.
2.3 Procedure
1. Before starting, in a sterile tube put 9.8 mL of 1×ACP buffer at 56°C. Also let 
warming some Petri dish (or rectangular plate) in the 56°C incubator.
2. Preparation of chicken erythrocytes (CE) for ACP assay
Biochemical Testing - Clinical correlation and Diagnosis
4
a. Under aseptic conditions, remove 100  μl packed CE from stock chicken 
blood stored in Alsever’s solution.
b. Wash twice in ACP buffer.
c. Resuspend in the same buffer to the required concentration for assay by 
2.1 mL of ACP buffer and put the cell suspension in a water bath at a tem-
perature of 46°C.  The concentration of CE can be calculated by lysing 
0.1 mL of the stock CE in 2.9 mL H2O and measuring the absorbance of the 
supernatant at 412 nm.
3. Melt 2% agarose stock (most conveniently in a microwave oven although 
immersion in boiling water will suffice) and, using a warm pipet, pipet 
12.25 mL aliquots into universal containers (one for each gel), keep at 56°C.
4. Add the 9.8 mL warmed 1×ACP (56°C) to each bottle of melted agarose. Mix 
well.
Transfer one bottle with diluted agarose to 45°C and allow to cool to this tempe 
rature.
5. To ease pouring the gel, place the warmed Petri dish (or rectangular plate) on 
level tray. Mix carefully and quickly.
6. Pour the mixture evenly onto the level plate. The mixture should go to the mid 
edges of the Petri dish/rectangular plate. Remove bubbles by touching them 
with a pipette tip or gloved finger.
7. Cool plate to 4°C, punch holes using a Pasteur pipette upside down at least 
1 cm apart.
8. Fill wells with a measured serum volumes (30 μL). Include a normal human 
plasma (NHP) standard, and NHP diluted 1/2 and 1/4 on each individual dish/
plate. The size of rings depends on factors such as gel thickness, and NHP 
standards are needed on each dish.
9. Incubate overnight at 4°C, examine Petri dish before transferring to 
37°C. Incubate at 37°C for 1–2 h. Incubate either overnight at 22°C and 2 h at 37°C.
10. Measure the diameters of the rings of lysis and calculate the areas. Areas of 
lysis can be read after photography, or after making direct photographic prints, 
but this is optional.
11. Standard curve: A crude standard curve is drawn by plotting % concentration 
NHP vs. area of lysis (diameter squared can also be used). This allows calcula-
tion of % normal activity in test samples.
3. Representative results
After incubation, the ACP activity is calculated after measuring the diameter 
using the vernier caliper or taking the ACP dish in photo and measure each surface 
well by Image J® (Figure 1). Area surfaces are calculated by the formula S = π*r2, 
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with r = d/2. (r: radius, d: diameter, s: surface). The same procedure is applied to the 
different NHP dilutions included to establish the calibration curve. This is because 
diluting NHP means that all ACP components are diluted equally. As example of 
interpretation, the more the ring is small the more the effectiveness of Eculizumab 
is good. The absence of reaction in a well signifies a complete ACP blockage, either 
by a drug or by a pathological process.
3.1 Materials
1. Chicken erythrocytes (CE) conserved in Alsever’s solution.
2. Phosphate-buffered saline (PBS).
3. Veronal buffered saline (VBS).
4. Gelatin veronal buffer (GVB).
5. AP buffer is GVB containing 5 mM Mg and 5 mM ethylene glycol bis[β-
aminoethylether]N,N′-tetraacetic acid (EGTA, E4378 Sigma).
6. N-saline is 9 g NaCl dissolved in 1 L H2O.
7. Barbitone buffer is made by mixing 0.1 M solutions of sodium barbitone and 
barbituric acid to obtain the target pH and adjusting volume to obtain required 
final molarity.
3.2 Equipment
1. Suitable Petri dishes or glass plates. Size depends on the number of samples. 
Volumes can be adjusted so that the final depth of the gel is ~1–1.5 mm.
2. 56°C incubator and dishes/plate warmer (water bath can also be used).
3. 46°C water bath.
Figure 1. 
ACP dishes for different sera from patients and pooled normal plasmas NHP. (A) Rings size of well 1 and 
9 are found in a complete ACP blockade by Eculizumab or total deficiency of one of the ACP proteins. The 
remaining wells show different plasmatic levels of ACP. (B) Sera tested in this ACP dish are within normal 
range but vary according to the clinical presentation.




6. Pasteur pipette as well cutters to produce holes approximately 5 mm diameter. 
If single holes are to be punched, a grid should be placed under the gel so that 
the holes can be distributed evenly.
7. Refrigerated centrifuge.
8. Electronic balance.
9. pH meter/temperature probe.
4. Discussion
Since Thomas A. E. Platts-Mills and Kimishige Ishizaka have discovered that 
fresh normal human serum in EGTA buffer was found to cause >90% hemolysis 
of unsensitized rabbit red blood cells (RaRBC) [11], simple timed lysis assay and 
dilution methods called AP50 (Alternative Pathway 50) was performed to quantify 
hemolytic complement activity in human serum [13–15]. This reaction requires 
C3, factors B and D, and Mg++ ions to form the C3 convertase (C3bBb) [14, 15]. 
In AP50, ACP is activated and measured by virtue of RaRBC decreased sialic acid 
content in addition to the blockade of the classical pathway activation by chelation 
of calcium by EGTA [16]. Nonetheless, AH50 requires a lot of material like spec-
trophotometer and consumable test tubes and highly skillful personal. To adapt 
this assay to simple labs, a semi-solid phase assay was proposed to measure ACP 
activity by using chicken erythrocytes incorporated in agarose gel called AP100. 
Cell membranes of chicken erythrocytes have the same properties as those of the 
Fluid phase assay (AH50) Semi-solid phase assay (AP100)
Number of samples <5 per day Several samples series per day
ACP Activators Red cells Red cells + agarose particles
End point assessment Optical density by 
Spectrophotometer
Diameter measurement directly
Laboratory work flow steps +++ Less
Time consuming +++ Less
Storage No 15–21 days
Transport No Yes (respecting the cold chain)
Global cost +++ Less
Assay related error +++ Less
Manipulator linked error +++ Less
Others • More suitable complement related 
diseases screening
• Do not need a deep immunotechnol-
ogy handling
• Storage of utilized plates for intra and 
inter-laboratory comparisons
Table 2. 
Hemolytic agarose assay features in comparison to tube hemolytic assay.
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rabbit in terms of cell surface charge density of sialic acid whereas they are more 
robust than rabbit because they have nuclei. AP100 assay has many advantages over 
the AH50 one (Table 2). For example, AP100 is more reliable for the eculizumab 
monitoring as shown in the article we have recently reviewed [17]. Moreover, AH50 
still challenging in low incomes country laboratories that cannot equip their hos-
pital and research laboratories to perform this assay. To overcome this roadblock, 
it was proceeded to render this method more practical to each laboratory with a 
purpose to be stored and transported for several weeks. This includes a hemolytic 
agarose dishes/plates; a special adaptation to prevent complement activation via 
the classical pathway and facilitate complement activation via the alternative one 
in agarose gels.
To the best of our knowledge there were no laboratory performing that assays in 
developing countries especially in Africa and no educational chapter is available to 
explain it. Once its optimization in each of these countries laboratories was per-
formed, thanks to ACP dishes/plates, we are expecting to empower doctors’ decision 
making process and improve quality of patients’ management and therapy follow-up. 
Therefore this portable and easy to use device even at the bedside of the patient and 
in the companion do not necessitate any equipped laboratory and may facilitate 
prospective analysis and disease screening in large populations. With enlargement of 
the ACP disease spectrum necessitated complement blockade, AP100 should be con-
sidered by clinical laboratory scientist especially to analyze sets of samples at once.
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